Literature DB >> 9768753

Kinetics of interaction of HLA-C ligands with natural killer cell inhibitory receptors.

M Valés-Gómez1, H T Reyburn, M Mandelboim, J L Strominger.   

Abstract

The recognition of HLA-C molecules by specific inhibitory receptors is a crucial step in the regulation of natural killer (NK) cell function. Using soluble, recombinant HLA-C molecules and NK inhibitory receptors (NKIR, members of the immunoglobulin superfamily), we show that HLA-C binds to NKIR molecules with extremely fast association and dissociation rates, among the fastest of the immune system interactions so far studied. These kinetics may be essential for the biological function of NK cells, i.e., to facilitate the rapid immunosurveillance of cells for absent or diminished expression of class I MHC proteins.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9768753     DOI: 10.1016/s1074-7613(00)80616-0

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  29 in total

1.  The human natural killer cell immune synapse.

Authors:  D M Davis; I Chiu; M Fassett; G B Cohen; O Mandelboim; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

Review 2.  The CD94/NKG2 family of receptors: from molecules and cells to clinical relevance.

Authors:  Francisco Borrego; Madhan Masilamani; Alina I Marusina; Xiaobin Tang; John E Coligan
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

3.  Tethering IL2 to Its Receptor IL2Rβ Enhances Antitumor Activity and Expansion of Natural Killer NK92 Cells.

Authors:  Youssef Jounaidi; Joseph F Cotten; Keith W Miller; Stuart A Forman
Journal:  Cancer Res       Date:  2017-09-15       Impact factor: 12.701

4.  Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors.

Authors:  C Andrew Stewart; Fanny Laugier-Anfossi; Frédéric Vély; Xavier Saulquin; Jenifer Riedmuller; Agnès Tisserant; Laurent Gauthier; François Romagné; Géraldine Ferracci; Fernando A Arosa; Alessandro Moretta; Peter D Sun; Sophie Ugolini; Eric Vivier
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-02       Impact factor: 11.205

5.  Enhanced lymphocyte interferon (IFN)-γ responses in a PTEN mutation-negative Cowden disease kindred.

Authors:  R Stevenson; A Fatehullah; I Jagan; R K Deevi; V Bingham; A E Irvine; M Armstrong; P J Morrison; I Dimmick; R Stewart; F C Campbell
Journal:  Clin Exp Immunol       Date:  2011-03-01       Impact factor: 4.330

6.  The activating Ly49W and inhibitory Ly49G NK cell receptors display similar affinities for identical MHC class I ligands.

Authors:  Brian J Ma; Carla M Craveiro Salvado; Kevin P Kane
Journal:  Immunogenetics       Date:  2014-05-07       Impact factor: 2.846

7.  Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR.

Authors:  Noa Stanietsky; Tihana Lenac Rovis; Ariella Glasner; Einat Seidel; Pinchas Tsukerman; Rachel Yamin; Jonatan Enk; Stipan Jonjic; Ofer Mandelboim
Journal:  Eur J Immunol       Date:  2013-07-04       Impact factor: 5.532

8.  Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G.

Authors:  Mitsunori Shiroishi; Kouhei Tsumoto; Kimie Amano; Yasuo Shirakihara; Marco Colonna; Veronique M Braud; David S J Allan; Azure Makadzange; Sarah Rowland-Jones; Benjamin Willcox; E Yvonne Jones; P Anton van der Merwe; Izumi Kumagai; Katsumi Maenaka
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-09       Impact factor: 11.205

9.  Bovine leukemia virus SU protein interacts with zinc, and mutations within two interacting regions differently affect viral fusion and infectivity in vivo.

Authors:  Jean-Stéphane Gatot; Isabelle Callebaut; Carine Van Lint; Dominique Demonté; Pierre Kerkhofs; Daniel Portetelle; Arsène Burny; Luc Willems; Richard Kettmann
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

Review 10.  Biology and clinical impact of human natural killer cells.

Authors:  Sherif S Farag; Jeffrey B VanDeusen; Todd A Fehniger; Michael A Caligiuri
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.